JULY 2014
Asian-Pacific Society
of Atherosclerosis
and Vascular Diseases
&
East
Meets
West Symposium
25 28 September 2014
Asian-Pacific Society
of Atherosclerosis
and Vascular Diseases
&
East
Meets
West Symposium
26 28 September 2014
Hong Kong Convention and Exhibition Centre
Please
8
Pleaserefer
refer to
to page
page 4
FORUM
Retaining health
workers for a
better community
CONFERENCE
Recommendations
in the management
of HIV
MT2014-APRIL-PH.indd 1
26/3/14 11:44 am
Find out what these experts have to say about how to improve
patient care for osteoporosis and sarcopenia in Asia through
awareness building and the use of new therapies
Professor
Peter Ebeling
Professor
Serge Ferrari
Dr Edith Lau
Professor Bess
Dawson-Hughes
Widespread vitamin D
deficiency and low calcium
levels in Asians
Selective estrogen
receptor modulators
(SERMs), a new class of
therapy for post-menopausal
woman with osteoporosis
J U LY 2 01 4
he Sin Tax Law reduced smoking prevalence among the younger sector and
among the poorest population, said Department of Health (DOH) acting secretary Nemesio
Gako in a press conference last May 30, 2014,
in Manila for the commemoration of World No
Tobacco Day. Together with the Department of
Finance (DOF) and World Health Organization
increased.
J U LY 2 01 4
secretary Ona.
facilities.
J U LY 2 01 4
FORUM
heart diseases.
The
J U LY 2 01 4
FORUM
diseases.
interventions.
awareness campaign.
J U LY 2 01 4
FORUM
Tayag.
2017.
Asian-Pacific Society
of Atherosclerosis
and Vascular Diseases
&
East
Meets
West Symposium
Youn
Invest g
igato
Award r
Symposium Themes
t Inflammation in Atherosclerosis and Vascular Diseases
t Asia Pacific Guidelines and Management for Familial Hypercholesterolemia
and Metabolic Syndrome
t Genetics and Environmental Interaction in Atherosclerosis
t Circadian Rhythm / Sleep Disorders in Diabetes and Atherosclerosis
t The Elderly and Diabetes
t Diabetes and the Liver
t Living with Diabetes Whats New
t Infections, Diabetes and Atherosclerosis
t Nutrition and Cardiovascular Risk
t Latest Guidelines on Management of Hypercholesterolaemia and
Hypertension
Early-bird Registration
Deadline for early-bird discounted fees is 31 July 2014
Congress Secretariat
and more talks covering latest advances in the management of diabetes and
cardiovascular disease. . . . . .
E-mail: info@eastmeetswest.org.hk
Organizers:
Hong Kong
Atherosclerosis Society
J U LY 2 01 4
FORUM
added Lorenzo.
maternal mortality.
J U LY 2 01 4
FORUM
10
need.
each municipality.
J U LY 2 01 4
FORUM
11
es in the area.
which in the long run could help improve careers and opportunities.
Challenges ahead
Based on projections of human resources for various health disciplines from 2005 to
2030, Lorenzo stated that we are not meeting
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
12
pines is increasing at an alarming rate, according to Dr. Edsel Salvaa, associate professor
with the National Institutes of Health - University
of the Philippines Manila.
From a worldwide perspective, the world has
decreased the number of new cases by 33 percent in the same time period that we increased
the number of our HIV cases by 2,667 percent,
stated the speaker.
ment of AIDS.
system.
since 2005.
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
13
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
14
the management of HIV disease and other comorbidities are being handled by primary care
providers.
HIV transmission
7 percent.
HIV testing
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
15
Management of HIV
The current recommended regimen for HIV
with lopinavir/ritonavir.
to fulminant hepatitis.
tuberculosis.
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
16
tance.
ture.
lists are provided by some publications to facilitate submission. The most common reason for
manuscripts not being accepted is failure to follow the instructions, said Tort.
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
17
excluded.
excluded.
Discussion. Conclusions are based on evidence. Key findings are summarized first (re-
consistent in both places. Oftentimes, the abstract is the only section that is read. Careful
Other tips
on the Internet.
and
post a hypothesis. Around 500 words will suffice but always check the journals instructions
script.
Ensure that the references follow the required format.
Ensure that references cited in text appear
in the bibliography.
5th 5-Continent-Congress
11th 13th December, 2014 Hong Kong
www.5-CC2014.com
L a s e r s
a n d
a e s t h e t i c
M e d i c i n e
PRELIMINARy FACuLTy
WORKSHOP HIGHLIGHTS
Laser
Botulinum Toxin
Fillers
Body Contouring
IMPORTANT TIMELINES
Deadline for Abstract Submission: 31 July 2014
Deadline for Early Bird Registration: 31 August 2014
VENuE
Hong Kong Convention and Exhibition Centre
1 Expo Drive, Wanchai, Hong Kong
CONGRESS SECRETARIAT
5th 5-CONTINENT-CONGRESS
CONGRESS PRESIDENT
5-CONTINENT-CONGRESS
BOARD MEMBERS
Maurice Adatto (Switzerland)
Christine Dierickx (Belgium)
Klaus Fritz (Germany)
Michael Gold (USA)
David Goldberg (USA)
Moshe Lapidoth (Israel)
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
19
Jonkman, an instructor and primary care clinical pharmacist from the School of Pharmacy of
tions.
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
20
ART regimens
There are three ART regimens for HIV treat-
Example cases
of her gender, CD4 count, concomitant medications and co-morbidities, the most appropriate
ment failure
plus efavirenz.
toxicity.
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
21
statins, etc.
non-adherence.
Join Us
For the Latest Updates on
Asthma: Asthma-COPD Overlap Syndrome
Lung Infection (Non-TB): Pneumonia and Sepsis
Whats New
Asthma: What is in the Pipelines in Asthma Therapy
Asthma: Severe Asthma Whats New
Lung Infection (TB): ISTC to Ensure Quality of Care
Lung Infection (TB): Achieving Zero TB Making
Bronchoscopy and Interventional Technique
Cellular and Molecular Biology: Hot Topics in
It Happen
Lung Infection (TB): TB Risk Factors and Intervention
Lung Cancer: Mediastinal Tumor
Lung Cancer: Targeted Strategies and Beyond in NSCLC
COPD: Redefining COPD
Lung Cancer: Whats New in Small Cell Lung Cancer
COPD: Management of Chronic Respiratory Disease
Critical Care: Whats New in Pulmonary Oedema
Interstitial Lung Disease: Rare and Orphan
Lung Disease
Lung Disease
Paediatrics: Childhood Obstructive Sleep Apnoea
An Update
Interstitial Lung Disease: Idiopathic Pulmonary
Fibrosis
Pulmonary Circulation: Whats New in Pulmonary
Hypertension
Lung Infection (Non-TB): Community Acquired
Respiratory Neurobiology and Sleep: Advances in
In partnership with:
J U LY 2 01 4
F E ATU R E
23
routinely orders baseline lipid profiles and electrocardiogram for all his hypertensive patients
during their first consult. Is the doctor in a conflict of interest?
Dr. Guia Crisostomo Tan, bioethics expert and
ENT consultant with The Medical City, posed
this question during the 44th Annual Convention
of the Philippine College of Physicians held last
tance of even small gifts can affect clinical judgment and heighten the perception and/or reality
of a conflict of interest, states the ACP-ASIM.
J U LY 2 01 4
F E ATU R E
24
a public website.
J U LY 2 01 4
F E ATU R E
of interest?
25
ed by personal self-interests.
A call to action
services.
J U LY 2 01 4
M A R K E T WATC H
26
pore brought in cancer experts to talk on new approaches to treating cancer last May 16 and 17,
2014.
Dr. Ang Peng Tiam, medical director of Park-
Drs. Ang Peng Tiam and Lim Ziyi answering the questions
during the May 16 CME.
dition warrants it. It has been reportedly successfully used in other countries to treat autoimmune disorders and certain solid tumors.
Boy Abunda, celebrity host, graced the occasion and shared with the media some real life
J U LY 2 01 4
M A R K E T WATC H
27
its first postgraduate course in critical care pharmacy on April 12 to 14, 2014. A total of 157 participants the program.
The programs objectives were to provide
updated knowledge on ICU practices, protocols and guidelines; develop critical thinking
J U LY 2 01 4
MA R K E T WATC H
28
GNC store.
contact tracing.
J U LY 2 01 4
N E WS
29
advance directives.
fornia, US.
2014:doi:10.1371/journal.pone.0098246;JAMA
1989; 262:24152419]
directives favorably.
advance directives.
cians.
make decisions.
J U LY 2 01 4
N E WS
30
J U LY 2 01 4
N E WS
32
time sleepiness.
J U LY 2 01 4
N E WS
33
ers say.
algia.
J U LY 2 01 4
N E WS
34
ther measure. Using both BMI and WHtR together reduced the number of high-risk indi-
insulin
resistance,
cardiometabolic-feature
spectively.
696]
SPONSORED
SYMPOSIUM
HIGHLIGHTS
SPONSORED
SYMPOSIUM
HIGHLIGHTS
Simplifyingattainment
attainmentof
oftarget
targetHbA1c:
HbA1c:
Simplifying
Fromclinical
clinicaltrial
trialto
toreal-life
real-lifepractice
practice
From
industry-sponsored
symposium
held
Sofitel
Philippine
Plaza
October
2013,
healthcare
professionals
attended
interactive
meeting
In In
anan
industry-sponsored
symposium
held
atat
Sofitel
Philippine
Plaza
onon
October
21,21,
2013,
healthcare
professionals
attended
anan
interactive
meeting
titled,
The
Milestones
A Decade
Clinical
Experience
Simplifying
Attainment
Target
A1c:
From
Clinical
Trial
Real
Life
Practice.
The
lecture
titled,
The
Milestones
ofof
A Decade
ofof
Clinical
Experience
Simplifying
Attainment
ofof
Target
A1c:
From
Clinical
Trial
toto
Real
Life
Practice.
The
lecture
was
conducted
diabetes
expert,
Augusto
Litonjua,
who
highlighted
the
significance
and
benefits
premix
insulin,
particularly
biphasic
was
conducted
byby
diabetes
expert,
DrDr
Augusto
DD
Litonjua,
who
highlighted
the
significance
and
benefits
ofof
premix
insulin,
particularly
biphasic
insulin
aspart
(BIAsp)
(NovoMix
Novo
Nordisk),
the
management
diabetes.
insulin
aspart
(BIAsp)
3030
(NovoMix
30,30,
Novo
Nordisk),
in in
the
management
ofof
diabetes.
Dr Augusto
D Litonjua
Dr Augusto
D Litonjua
EMERITUS
PROFESSOR,
COLLEGE
OF MEDICINE,
EMERITUS
PROFESSOR,
COLLEGE
OF MEDICINE,
UNIVERSITY
OF THE
PHILIPPINES,
MANILA
UNIVERSITY
OF THE
PHILIPPINES,
MANILA
PRESIDENT,
PHILIPPINE
CENTER
DIABETES
PRESIDENT,
PHILIPPINE
CENTER
FORFOR
DIABETES
EDUCATION
FOUNDATION,
EDUCATION
FOUNDATION,
INC INC
5
glycemia
mortality.
It has
been
proven
that
post-prandial Figure
Figure
3. The
1-2-3
Study:
Point
reduction
in HbA1c
with
OD,
glycemia
andand
mortality.
It 5 has
been
proven
that
post-prandial
3. The
1-2-3
Study:
Point
reduction
in HbA1c
with
OD,
plasma
glucose
(PPG)
elevation
after
lunch
predicts
cardiovascu- BIDBID
or TID
BIAsp
plasma
glucose
(PPG)
elevation
after
lunch
predicts
cardiovascuor TID
BIAsp
30123012
(CV)
better
than
other
glycemic
parameters
in type
2 dia- 10 10
lar lar
(CV)
riskrisk
better
than
other
glycemic
parameters
in type
2 diabetes
(Table
betes
(Table
1).61).6
9 9
8 8
Figure
1 Pathophysiology
of type
2 diabetes:
Figure
1 Pathophysiology
of type
2 diabetes:
1
1
Failure
of mealtime
insulin
secretion
Failure
of mealtime
insulin
secretion
8.6%
8.6%
HbA1c (%)
6 6
5
6.6%
6.6%
4 4
3
0 0
Baseline
Baseline
OD,OD,
BID,BID,
TIDTID
= once
= twice
= thrice
HbA1c
= hemoglobin
OD =OD
once
daily;daily;
BID =BID
twice
daily;daily;
TID =TID
thrice
daily;daily;
HbA1c
= hemoglobin
A1c;A1c;
BIAsp
= biphasic
insulin
aspart
BIAsp
= biphasic
insulin
aspart
*p<0.01
for comparison
between
women
and men
(post-lunch
values),
n=592
*p<0.01
for comparison
between
women
and men
(post-lunch
values),
n=592
CI = confidence
interval;
= fasting
plasma
glucose;
HbA1c
= hemoglobin
CI = confidence
interval;
FPG FPG
= fasting
plasma
glucose;
HbA1c
= hemoglobin
A1c;A1c;
= hazard
HR =HR
hazard
ratio.ratio.
In the
ASEAN
region,
overall
of BIAsp
showed
a signifiIn the
ASEAN
region,
thethe
overall
useuse
of BIAsp
30 30
showed
a significant
reduction
(-2.5)
in baseline
HbA1c
overall
incidences
reduction
(-2.5)
in baseline
HbA1c
andand
lessless
overall
incidences
In
a 2003
study
comparing
relative
contribution
both cant
a 2003
study
comparing
thethe
relative
contribution
of of
both
of hypoglycemia
after
weeks.
Patients
showed
improvements
after
24 24
weeks.
Patients
showed
improvements
FPG
PPG
levels
diurnal
hyperglycemia
showed
that
both of hypoglycemia
FPG
andand
PPG
levels
to to
diurnal
hyperglycemia
showed
that
both
in self-rated
health
scores
while
using
BIAsp
preparation.
health
scores
while
using
thethe
BIAsp
30 30
preparation.
contribute
overall
daily
glycemic
load
at all
HbA1c
levels. in self-rated
contribute
to to
thethe
overall
daily
glycemic
load
at all
HbA1c
levels.
15 15
Weight
changes
were
minimal
(Table
changes
were
alsoalso
minimal
(Table
2). 2).
They
particularly
have
approximately
equal
contribution
when Weight
They
particularly
have
approximately
equal
contribution
when
7
7
HbA1c
levels
range
from
to 9.2.
HbA1c
levels
range
from
7.37.3
to 9.2.
15 15
Table
2. Overall
NovoMix
in the
ASEAN
region
Table
2. Overall
NovoMix
30 30
useuse
in the
ASEAN
region
In terms
of management,
Nippon
ultra-rapid
Insulin
In terms
of management,
thethe
Nippon
ultra-rapid
Insulin
andand
dia-diaChange
Baseline
Efficacy
Change
in in
Baseline
Efficacy
betic
Complication
Evaluation
(NICE)
study
compared
longbetic
Complication
Evaluation
(NICE)
study
compared
thethe
longHbA
HbA
Change
in PPG
Change
in PPG
HbA
HbA
Change
in PPG
Change
in PPG
1c 1c
1c 1c
term
of insulin
aspart
human
regular
insulin,
showed
term
useuse
of insulin
aspart
andand
human
regular
insulin,
andand
showed
a lower
cumulative
incidence
of CV
events
among
insulin
aspart
a lower
cumulative
incidence
of CV
events
among
insulin
aspart
9.9%
2.5% 5.1 5.1
mmol/L 7.47.4
mmol/L
2.5%
mmol/L
mmol/L
NovoMix
30 30 9.9%
users.
Analysis
variance
in blood
glucose
parameters
such
users.
Analysis
of of
variance
in blood
glucose
parameters
such
as as NovoMix
Normal
subjects Patients
Patients
2 diabetes
Normal
subjects
withwith
typetype
2 diabetes
<8 mmol/L FPGFPG
mmol/L
FPGFPG
<8 mmol/L
12-1512-15
mmol/L
In
<12 mmol/L FPGFPG
18 mmol/L
FPGFPG
<12 mmol/L
18 mmol/L
0.800.80
1.001.00
7
HbA1c (%)
Table
1. Cardiovascular
in association
with
glycemic
Table
1. Cardiovascular
riskrisk
in association
with
glycemic
6 6
parameters
in type
2 diabetes
in type
2 diabetes
Insulin
kinetics
is an
important
factor
in the
management
of dia- parameters
Insulin
kinetics
is an
important
factor
in the
management
of diabetes.
Normal
insulin
secretion
is divided
three
phases.
In the Model
betes.
Normal
insulin
secretion
is divided
intointo
three
phases.
In the
tertile
vs 1st
(95%
HRHR
for for
3rd3rd
tertile
vs 1st
andand
2nd2nd
(95%
CI) CI)
Model
pathophysiology
of type
2 diabetes,
there
is insufficient
baseline
pathophysiology
of type
2 diabetes,
there
is insufficient
baseline
Men
Women
Men
Women
insulin
well
a failure
of mealtime
insulin
secretion.
This
insulin
as as
well
as as
a failure
of mealtime
insulin
secretion.
This
de-de- FPGFPG
(0.35-1.54) 2.342.34
(0.66-8.20)
0.730.73
(0.35-1.54)
(0.66-8.20)
is marked
even
with
fasting
plasma
glucose
(FPG)
levels
fectfect
is marked
even
with
fasting
plasma
glucose
(FPG)
levels
of of PPGPPG
h after
lunch)
(1.04-4.32) 5.545.54
(1.45-21.20)*
(2 h(2after
lunch)
2.122.12
(1.04-4.32)
(1.45-21.20)*
than
8 mmol/L
(Figure
lessless
than
8 mmol/L
(Figure
1).11).1
HbA1c
(0.55-2.21) 1.351.35
(0.43-4.26)
HbA1c
1.111.11
(0.55-2.21)
(0.43-4.26)
0.600.60
0.400.40
0.200.20
0.000.00
-30 -30 0 0 30 30 60 60 90 90120120150150180180210210240240
Time
(minutes)
Time
(minutes)
FPG,
PPG
HbA1c
showed
better
overall
glycemic
control
FPG,
PPG
andand
HbA1c
alsoalso
showed
better
overall
glycemic
control
= fasting
plasma
glucose
FPG FPG
= fasting
plasma
glucose
Safety
Safety
Other
Other
in the
insulin
aspart
group
within
5 years
of use
(Figure
insulin
aspart
group
within
5 years
of use
(Figure
2). 2).
physiological
insulin
profile
is composed
a basal
component in the
TheThe
physiological
insulin
profile
is composed
of aofbasal
component
Weight
Change
Weight
Change
Hypoglycemia
Hypoglycemia
meal-related
peaks.
Soluble
human
insulin
preparations
andand
meal-related
peaks.
Soluble
human
insulin
preparations
failfail
Figure
2.
Cumulative
incidences
of
primary
composite
endpoints
Figure
2.
Cumulative
incidences
of
primary
composite
endpoints
to match
normal
insulin
peaks
because
of their
slow
absorption,
to match
normal
insulin
peaks
because
of their
slow
absorption,
0.9*
0.9*
NovoMix
NovoMix
30 30
between
long-term
insulin
aspart
human
regular
long-term
useuse
of of
insulin
aspart
andand
human
regular
resulting
in postprandial
hyperglycemia.
Intermediate-acting
resulting
in postprandial
hyperglycemia.
Intermediate-acting
in- in- between
8 8
*Significant
improvement
(p<0.001)
*Significant
improvement
(p<0.001)
insulin
insulin
sulin
provides
better
basal
insulin
replacement,
even
when
sulin
provides
better
basal
insulin
replacement,
butbut
even
when
HbA1c
= hemoglobin
= postprandial
plasma
glucose
HbA1c
= hemoglobin
A1c;A1c;
PPGPPG
= postprandial
plasma
glucose
combined
with
regular
insulin,
it fails
to recreate
physiological
combined
with
regular
insulin,
it fails
to recreate
thethe
physiological
Cumulative
incidence
of primary
composite
endpoint
Cumulative
incidence
of primary
composite
endpoint
There
are
several
ongoing
trials
on
BIAsp
such
as the
SimpleThere
are
several
ongoing
trials
on
BIAsp
30,30,
such
as the
Simpleinsulin
profile.
insulin
profile.
Mix
which
aims
to compare
investigator
vs patient-driven
Mix
trialtrial
which
aims
to compare
investigator
vs patient-driven
11 11
Human
regular
insulin
(11.1%)
Human
regular
insulin
(11.1%)
titration
schemes
SimpleMix
trial),
Sit2Mix
which
titration
schemes
(ie,(ie,
SimpleMix
trial),
thethe
Sit2Mix
trialtrial
which
Insulin
aspart
(6.4%)
aspart
(6.4%)
better
manage
diabetes,
newer
preparations
mimic
To To
better
manage
diabetes,
newer
preparations
mimic
thethe
du-du- 10 10 Insulin
is investigating
effects
of adding
or substituting
BIAsp
is investigating
thethe
effects
of adding
or substituting
BIAsp
30 30
to to
9 9
al-release
insulin
concept
combining
rapid-acting
insual-release
insulin
concept
by by
combining
thethe
rapid-acting
insu8 8
sitagliptin,
EasyMix
which
is studying
efficacy
sitagliptin,
andand
thethe
EasyMix
trialtrial
which
is studying
thethe
efficacy
of of
analogues
with
basal
insulin
provide
physiologic
insulin
lin lin
analogues
with
basal
insulin
to to
provide
physiologic
insulin
7 7
BIAsp
insulin
glargine
(both
in combination
with
metBIAsp
30 30
andand
insulin
glargine
(both
OD)OD)
in combination
with
metreplacement.
This
is where
analogue
premixes
such
BIAsp
replacement.
This
is where
analogue
premixes
such
as as
BIAsp
30 30
6 6
16 16
formin
glimepiride.
formin
andand
glimepiride.
(NovoMix
used
to replace
both
meal-related
basal
(NovoMix
30)30)
cancan
be be
used
to replace
both
meal-related
andand
basal
insulin
levels.
insulin
levels.
5 5
4 4
3 3
2 2
1 1
0 0
0 0
Summary
Summary
Since
launch
years
ago,
BIAsp
shown
great
promSince
its its
launch
10 10
years
ago,
BIAsp
30 30
hashas
shown
great
promBIAsp
a time-tested
molecule
since
launch
in 2002,
BIAsp
30 30
is aistime-tested
molecule
since
its its
launch
in 2002,
in better
managing
type
2 diabetes
to the
wealth
of data
ise ise
in better
managing
type
2 diabetes
duedue
to the
wealth
of data
it has
since
received
approval
in the
elderly,
in children
it has
since
received
approval
forfor
useuse
in the
elderly,
in children
supported
numerous
randomized
controlled
trials
well
supported
by by
numerous
randomized
controlled
trials
as as
well
as as
years
of age,
in patients
switching
from
human
premix,
1010
years
of age,
in patients
switching
from
human
premix,
andand
1 1
2 2
3 3
4 4
5 5
real-world
clinical
experience
from
observational
studies.
It can
real-world
clinical
experience
from
observational
studies.
It can
Duration
(years)
Duration
(years)
in combination
with
anti-diabetic
drugs
(OADs).
It has
been
in combination
with
oraloral
anti-diabetic
drugs
(OADs).
It has
been
mimic
physiologic
insulin
secretion,
thus
providing
good
glycemic
mimic
physiologic
insulin
secretion,
thus
providing
good
glycemic
widely
used
in the
Europe
Asia.
Moreover,
in the
past
widely
used
in the
US,US,
Europe
andand
Asia.
Moreover,
in the
past
10 10
control
in all
parameters
monitored
FPG,
PPG
HbA1c).
in all
parameters
monitored
(ie,(ie,
FPG,
PPG
andand
HbA1c).
It It
years,
BIAsp
30 has
treated
millions
of patients
equivalent
to 10.7 There
years,
BIAsp
30 has
treated
millions
of patients
equivalent
to 10.7
There
a wealth
information
from
randomized
clinical
trials control
is aiswealth
of of
information
from
randomized
clinical
trials
is easily
titrated
a simple
intensified
dosing
regimen,
titrated
viavia
a simple
intensified
dosing
regimen,
andand
it it
2,3 2,3
million
patient-years.
million
patient-years.
that
show
significant
evidence
in favor
of BIAsp
in terms
of im- is easily
that
show
significant
evidence
in favor
of BIAsp
30 30
in terms
of imis relatively
safe
with
adverse
effects
such
hypoglycemia
safe
with
lessless
adverse
effects
such
as as
hypoglycemia
proving
HbA1c,
FPG,
PPG
rates
of hypoglycemia
with
simple is relatively
proving
HbA1c,
FPG,
PPG
andand
rates
of hypoglycemia
with
simple
weight
changes
regardless
of the
number
of injections.
These
andand
weight
changes
regardless
of the
number
of injections.
These
9,10,11
9,10,11
Dual-release
insulin
replacement
several
benefits,
which
Dual-release
insulin
replacement
hashas
several
benefits,
which
in- in- titration
titration
intensification
(N=1,121).
andand
intensification
(N=1,121).
consequently
provide
diabetic
patients
with
overall
good
willwill
consequently
provide
diabetic
patients
with
an an
overall
good
clude
mimicking
physiological
insulin
release
while
reducing
clude
mimicking
physiological
insulin
release
while
reducing
hy-hysense
of health
in turn,
help
prevent
mortality
morbidity
of health
andand
in turn,
help
prevent
mortality
andand
morbidity
poglycemic
compared
to conventional
premix.
It also
provides Aside
poglycemic
riskrisk
compared
to conventional
premix.
It also
provides
Aside
from
this,
real-world
clinical
experiences
based
from
this,
real-world
clinical
experiences
based
on on
ob-ob- sense
related
to poor
glycemic
control.
Further
studies
underway
to poor
glycemic
control.
Further
studies
areare
underway
to to
simplified
twice-daily
dosing
that
provide
satisfactory
glyce- servational
simplified
twice-daily
dosing
that
cancan
provide
satisfactory
glyceservational
studies
from
patients
coming
from
a wide
variety
studies
from
patients
coming
from
a wide
variety
of of related
help
better
maximize
potential
of this
preparation
in diabetes
better
maximize
thethe
potential
of this
preparation
in diabetes
control.
NovoMix
a biphasic
insulin,
which
a mixture therapies
micmic
control.
NovoMix
30 30
is aisbiphasic
insulin,
which
is aismixture
therapies
prove
that
there
is significant
improvement
alsoalso
prove
that
there
is significant
improvement
in in help
management.
of long-acting
insulin
aspart
(70%)
rapid-acting
insulin
aspart HbA1c
of long-acting
insulin
aspart
(70%)
andand
rapid-acting
insulin
aspart
HbA1c
levels
with
of BIAsp
that
there
is high
as high
levels
with
thethe
useuse
of BIAsp
30,30,
andand
that
there
is as
as as management.
References:
(30%).
This
combination
targets
both
fasting
mealtime
(30%).
This
combination
targets
both
fasting
andand
mealtime
glu-glu- a 2%
a 2%
- point
reduction
from
baseline
8.6%
to 6.6%)
with
once References:
- point
reduction
from
baseline
(ie,(ie,
8.6%
to 6.6%)
with
once
1. Coates
al. Diabetes
ResPract
Clin Pract
1994;26:177-87.
Health;
MIDAS,
March
3. NovoMix
1. Coates
PA, etPA,
al. et
Diabetes
Res Clin
1994;26:177-87.
2.IMS2.IMS
Health;
MIDAS,
March
2002 2002
April April
2011.2011.
3. NovoMix
4 4
30 Summary
of Product
Characteristics
4.NovoMix
30 Approved
Product
Information.
DECODE
of Product
Characteristics
(EU).(EU).
4.NovoMix
30 Approved
Product
Information.
5.The5.The
DECODE
StudyStudy
cose
at the
same
time.
cose
at the
same
time.
(OD),
twice
(BID)
or thrice
(TID)
daily
dosing
with
prepara- 30 Summary
(OD),
twice
(BID)
or thrice
(TID)
daily
dosing
with
thethe
saidsaid
preparaGroup.
Lancet
1999;354:617-21.
6. Cavalot
F, et
al. JEndocrin
Clin Endocrin
2006;91:813-9.
7. Monnier
L, et
al. Diabetes
Group.
Lancet
1999;354:617-21.
6. Cavalot
F, et al.
J Clin
MetabMetab
2006;91:813-9.
7. Monnier
L, et al.
Diabetes
Care Care
2003;26:881-5.
8. Nishimura
al. Diabetes
2008;57(Suppl
1):163-OR.
9. Raskin
P, et
al. Diabetes
Care 2005;28:2608. Nishimura
H, et H,
al. et
Diabetes
2008;57(Suppl
1):163-OR.
9. Raskin
P, et al.
Diabetes
Care 2005;28:260(Figure
Stepwise
regression
showed
that
there
tiontion
(Figure
3). 3).
Stepwise
regression
alsoalso
showed
that
there
waswas 2003;26:881-5.
10. Kann
PH,
al.Clin
ExpEndo
Clin Endo
2006;114:527-32.
11. Strojek
al. Med
Curr Res
MedOpin
Res Opin
2009;25:2887-944.
5. 10.5.Kann
PH, et
al.et
Exp
Diab Diab
2006;114:527-32.
11. Strojek
K, et K,
al.et
Curr
2009;25:2887-944.
With
regard
better
glycemic
control
diabetes
outcomes, no no
With
regard
to to
better
glycemic
control
andand
diabetes
outcomes,
correlation
with
hypoglycemia
between
phases/number 12. Garber
correlation
with
hypoglycemia
between
thethe
phases/number
12. Garber
al. Diabetes
2006;8:58-66.
13. Valensi
P, et
Int JPract
Clin Pract
2009;63:522-31.
14. Home
AJ, etAJ,
al. et
Diabetes
Obes Obes
MetabMetab
2006;8:58-66.
13. Valensi
P, et al.
Intal.
J Clin
2009;63:522-31.
14. Home
P, P,
al. Diabetes
ResPract
Clin Pract
2011;94:352-63.
15. Lim-Abrahan
MA,
al. Diabetes
ResPract
Clin Pract
2013;100(Suppl
1):S3-S9.
et al. et
Diabetes
Res Clin
2011;94:352-63.
15. Lim-Abrahan
MA, et
al. et
Diabetes
Res Clin
2013;100(Suppl
1):S3-S9.
12,13,14
12,13,14
studies
show
a significant
association
between
post-challenge of injections.
studies
show
a significant
association
between
post-challenge
of injections.
16. Liebl
al. Drugs
2012;30:72:1495-520.
16. Liebl
A, et A,
al. et
Drugs
2012;30:72:1495-520.
Novo
Nordisk
Pharmaceuticals
Novo
Nordisk
Pharmaceuticals
(Philippines)
(Philippines)
Inc. Inc.
Unit 2006,
20/FSan
OneMiguel
San Miguel
Ave. Bldg.,
San Miguel
Ave. cor.
Unit 2006,
20/F One
Ave. Bldg.,
San Miguel
Ave. cor.
Ortigas
Center,
City, Philippines
ShawShaw
Blvd.,Blvd.,
Ortigas
Center,
1605,1605,
PasigPasig
City, Philippines
Contact
Number:
667 3661
Contact
Number:
+632 +632
667 3661
Website:
www.novonordisk.com
Website:
www.novonordisk.com
MIMS
MIMS
Editorial
development
by MIMS.
opinions
expressed
in this
Editorial
development
by MIMS.
The The
opinions
expressed
in this
publication
arenecessarily
not necessarily
the editor,
publisher
or sponsor.
publication
are not
those those
of theofeditor,
publisher
or sponsor.
Any liability
or obligation
fororloss
or damage
howsoever
arising
is hereby
Any liability
or obligation
for loss
damage
howsoever
arising
is hereby
disclaimed.
MIMS.
2014 MIMS.
All rights
reserved.
Noofpart
this publication
may
be reproduced
disclaimed.
2014
All rights
reserved.
No part
thisofpublication
may be
reproduced
by anyby any
process
any language
without
the written
permission
the publisher.
process
in anyinlanguage
without
the written
permission
of theof
publisher.
MIMS
c/o MediMarketing,
MIMS
c/o MediMarketing,
Inc Inc
11/F BDO
Equitable
8751 Paseo
de Roxas,
1226 Makati,
Philippines
11/F BDO
Equitable
Tower,Tower,
8751 Paseo
de Roxas,
1226 Makati,
Philippines
T: 886
+6320333
886 0333
F: 886
+6320350
886 0350
T: +632
F: +632
E-mail:
enquiry.ph@mims.com
Website:
www.mims.com
E-mail:
enquiry.ph@mims.com
Website:
www.mims.com
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
36
Bellinzona, Switzerland.
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
37
alone.
Keynote Speakers:
Fetal Therapy
for Complicated
MC Twins
Prof Dennis LO
Necker-Enfants-Malades
Hospital, Paris Descartes
University
(Hong Kong)
President, International
Society of Ultrasound in
Obstetrics and Gynaecology
(ISUOG)
St Georges University of
London
President, International
Federations of Obstetrics
and Gynaecology (FIGO)
Non-Invasive
Prenatal DNA Testing:
Now & Future
Li Ka Shing Institute of
Health Sciences
Faculty:
Biswas ARJIT (Singapore)
TP BASKARAN (Malaysia)
Dear Colleague,
The Asia Pacific Congress in Maternal Fetal Medicine (APCMFM), established by the Fetal Medicine Foundation, United
Kingdom (www.fetalmedicine.com) and The Chinese Fetal Medicine Foundation, Hong Kong (www.fetalmedicine.hk),
convenes specialists doctors, trainees, nurses and allied health workers involved in the clinical and scientific aspects of
prenatal diagnosis, obstetrics, gynaecology, ultrasonography and genetics, in the field of maternal fetal medicine.
As the 10th APCMFM 2014 comes to be hosted in Singapore by the Obstetrical & Gynaecological Society, Singapore
in a fast-rising hub which healthcare resources and expert collaborations are engaging regional neighbours interests
we encourage you and your colleagues to come join the worlds leading minds in maternal fetal medicine today.
We warmly look forward to welcoming you here in Singapore at this 10th Anniversary occasion on 22-24 August 2014,
and be part of the conversations in maternal fetal medicine today.
Yours Sincerely,
Co-chairman
Hong Kong
Co-chairman
Singapore
Session 2.1
Ferring's Symposium 1: Born Too Early
Session 3.1
High Risk Labour
Chairpersons: LEUNG Tak Yeung (Hong Kong) & Tony TAN (Singapore)
Chairpersons: TBC
Obstetrical DIC
Session 1.2
Pre-Eclampsia: Prevention, Monitoring & Treatment
Session 2.2
Ferrings Symposium 2: Born Too Late
Session 3.2
Update in Antenatal Screening & Monitoring
Session 1.3
USG Meets Genetics
Session 2.3
Maternal Medicine: What Are Overlooked?
Speaker: TBC
Session 1.1
Advances in Intrapartum Monitoring & Management
of Birth Asphyxia
Chairpersons: LEUNG Tak Yeung (Hong Kong) &
Tony TAN (Singapore)
Session 3.3
Non-Invasive Prenatal Dna Testing (NIDT)
Chairpersons: LEUNG Tak Yeung (Hong Kong) & BUI The-Hung (Sweden)
IUGR and Macrosomia & Genetic / Genomic Syndromes Acquired and Inherited Thrombophilias Revisit
Session 3.4
Asia & Oceania Federation of Obstetrics & Gynaecology (AOFOG)
Session: Challenging the Conventional Practices
Session 1.4
How Good Is 1st Trimester Fetal Ultrasound?
Chairpersons: TBC
Session 2.4
Development of Fetal Therapy in Asia
Chairpersons: LEUNG Tak Yeung (Hong Kong) & Jonathan HYETT (Australia)
Speaker: S SURESH
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
40
stract LBA2]
hematologic toxicity.
den, he concluded.
J U LY 2 01 4
CO N F E R E N C E COV E R AG E
41
stract LBA3]
J U LY 2 01 4
I N P R AC TI C E
42
PE in Asia
Dr. Angela Ng
Family Physician and Sex Therapist
Ng Wing Ying Angela Clinic,
Hong Kong
diagnosis.
when a man experiences orgasm and expels semen too quickly after sexual activity with minimal penile stimulation. [J Urol 2008; 179(suppl),
340, abstract 988]
Misconceptions of PE
The general reluctance of individuals to speak
about PE together with the lack of awareness of
groups.
disposition.
J U LY 2 01 4
I N P R AC TI C E
43
anxiety.
Burden of PE
intimacy, which can eventually translate to problems in the relationship. Reports have indicated
2005;2:358-367]
societies.
Often, partners of men with PE are overlooked as the heavy impact it has on them is
PE is a treatable condition
J U LY 2 01 4
I N P R AC TI C E
44
Essential Clinical
Practice Tool
On-The-Go
www.mims.com
The FREE MIMS app delivers critical prescribing information, medical news
and CME articles as well as clinical calculators essential to physicians daily
practice needs.
With MIMS available across multiple platforms and devices, you can now easily
and conveniently find the most up-to-date and relevant drug information you
need anytime, anywhere.
facebook.com/mimscom
J U LY
19th WONCA Europe Conference
2/7/2014 to 5/7/2014
Location: Lisbon, Portugal
Info: Secretariat
Tel: (351) 217 712 634
Fax: (351) 217 712 639
Email: registration.wonca2014@
leading.pt
Website: http://woncaeurope2014.org
23rd Biennial Congress of the
European Association for Cancer
Research (EACR-23)
5/7/2014 to 8/7/2014
Location: Munich, Germany
Info: European CanCer Organisation
(ECCO)
Tel: (32) 2 775 02 01
Fax: (32) 2 775 02 00
Email: eacr23@ecco-org.eu
Website: www.ecco-org.eu/EACR23
20th International AIDS Conference
(AIDS 2014)
20/7/2014 to 25/7/2014
Location: Melbourne, Australia
Info: AIDS 2014 Secretariat
Tel: (41) 22 710 0800
Email: info@aids2014.org
Website: www.aids2014.org
AUGUST
10th Asia Pacific Congress in
Maternal Fetal Medicine
22/8/2014 to 24/8/2014
Location: Singapore
Info: APCMFM Secretariat
Tel: (852) 2632 1535
Fax: (852) 2636 0008
Email: apcmfm@med.cuhk.edu.hk
Website: www.apcmfm.hk
Hospital Management Asia 2014
28/8/2014 to 29/8/2014
Location: Cebu City, Philippines
Info: Secretariat
Tel: (632) 846 8339
Email: efrensoliman@exedraevents.com
Website: www.
hospitalmanagementasia.com
J U LY 2 01 4
C A L E N DA R
46
J U LY 2 01 4
H U MO R
48
workshop 1 - Fillers
workshop 2 - botulinum Toxin
workshop 3 - Non-invasive body contouring
workshop 4 - Non-invasive Face Lifting and skin resurfacing
ProgrAMMe hIghLIghTs
Aesthetic
FAcULTy MeMBers
reconstructive
Australia
Malaysia
Uk
michael Leung
Lay-hooi Lim
david Lam
Tiew Teo
canada
new Zealand
Jenny Lin
cho pang
michael Klaassen
china
Thiam-chye Lim
colin song
Woffles Wu
singapore
Yi-lin cao
Jian-hua Gao
shu-zhong Guo
Qing-feng Li
Xiao-xi Lin
wei Xia
Hui Zhu
Taiwan
chien-tzung chen
Hung-chi chen
Yu-ray chen
ming-huei cheng
david chuang
Yur-ren Kuo
chung-sheng Lai
Jing-wei Lee
chil-hung Lin
sin-daw Lin
Lun-jou Lo
Yueh-bil Tang
Feng-chou Tsai
Fu-chan wei
Jung wu
France
wei-guo Hu
hong kong
Jimmy chan
Kai-ming chan
Tor chiu
King-man Ho
stephanie Lam
daniel Lee
George Li
sir Gordon wu
UsA
James chao
Lily chen
Lynn chen-Jeffers
david chiu
ernest chiu
Li-fei Guo
Henry Hsia
david Kung
andrew Lee
Gordon Lee
Kant Lin
william Lineaweaver
paul Liu
Foad Nahai
Lee pu
christine rohde
michael wong
June wu
Jack Yu
Toni Zhong
korea
dae-hwan park
IMPorTAnT DATes
deadline for abstracts submission:
deadline for early bird registration:
regIsTrATIon
10 august 2014
1 september 2014
VenUe
enqUIry
orGaNIZers
Hong Kong Society of Plastic,
Reconstructive & Aesthetic Surgeons
PUBLISHER
ADVERTISING ENQUIRIES:
Ben Yeo
CHINA
SENIOR EDITOR
Yang Xuan
Tel: (8621) 6157 3888
Email: enquiry.cn@mims.com
HONG KONG
MANAGING EDITOR
Greg Town
CONTRIBUTING EDITORS
P U B L I C AT I O N M A N A G E R
Monica Bhatia
Tel: (9180) 2349 4644
Email: enquiry.in@mims.com
Marisa Lam
KOREA
DESIGNERS
PRODUCTION
Christine Chok
ACCOUNTING MANAGER
PHILIPPINES
Minty Kwan
A D V E RT I S I N G C O - O R D I N AT O R
Rachael Tan
PUBLISHED BY
Wipa Sriwijitchok
Tel: (662) 741 5354
Email: enquiry.th@mims.com
VIETNAM
Kristina Lo-Kurtz
Tel: (852) 2116 4352
Email: kristina.lokurtz@mims.com
Medical Tribune is published 12 times a year (23 times in Malaysia) by MIMS Pte Ltd. Medical Tribune is on
controlled circulation publication to medical practitioners in Asia. It is also available on subscription to members
of allied professions. The price per annum is US$48 (surface mail) and US$60 (overseas airmail); back issues
at US$5 per copy. Editorial matter published herein has been prepared by professional editorial staff. Views
expressed are not necessarily those of MIMS Pte Ltd. Although great effort has been made in compiling and
checking the information given in this publication to ensure that it is accurate, the authors, the publisher
and their servants or agents shall not be responsible or in any way liable for the continued currency of the
information or for any errors, omissions or inaccuracies in this publication whether arising from negligence or
otherwise howsoever, or for any consequences arising therefrom. The inclusion or exclusion of any product
does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.
The information contained within should not be relied upon solely for final treatment decisions.
2014 MIMS Pte Ltd. All rights reserved. No part of this publication may be reproduced in any language,
stored in or introduced into a retrieval system, or transmitted, in any form or by any means (electronic,
mechanical, photocopying, recording or otherwise), without the written consent of the copyright owner.
Permission to reprint must be obtained from the publisher. Advertisements are subject to editorial acceptance
and have no influence on editorial content or presentation. MIMS Pte Ltd does not guarantee, directly or
indirectly, the quality or efficacy of any product or service described in the advertisements or other material
which is commercial in nature.
Philippine edition: Entered as second class mail at the Makati Central Post Office under Permit No. PS-326-01
NCR, dated 9 Feb 2001. Printed by Fortune Printing International Ltd, 3rd Floor, Chung On Industrial Bldg, 28
Lee Chung Street, Chai Wan, Hong Kong.
ISSN 1608-5086